S0916, A Phase II, Window Trial of the Anti-CCR2 Antibody MLN1202 in Patients With Bone Metastases
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2015
At a glance
- Drugs Plozalizumab (Primary)
- Indications Bone metastases
- Focus Biomarker; Therapeutic Use
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jun 2012 Planned end date changed from 1 Aug 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 17 Mar 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.